Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

June 20, 2018

Primary Completion Date

June 16, 2021

Study Completion Date

June 16, 2021

Conditions

Congenital Bleeding DisorderHaemophilia A

Interventions

DRUG

turoctocog alfa

Patients will be treated with commercially available turoctocog alfa according to local clinical practice at the discretion of the physician

Trial Locations (1)

Novo Nordisk Investigational Site, Monterrey